Arcutis sees explosive growth as ZORYVE captures ~41% of non-steroidal psoriasis scripts, with improving margins. See why ARQT stock is upgraded to buy.
Arcutis Stock: ZORYVE’s Indication Momentum Margin Expansion Bullish Re
Seeking Alpha Stock3 hrs ago
65
The Motley Fool
Women's Wear Daily Retail
AlterNet
The Travel
Futurism